The World Health Organization's vaccine advisers now say one dose of HPV vaccine is the most efficient way to protect girls aged 9 to 14 against cervical cancer. But there is an important exception for our community: people living with HIV, even when HIV is well controlled, should keep getting at least two doses. The advisers announced the change in mid-October, and WHO's immunization director highlighted it in a message on October 29, 2026. Here is what the advisers said, why HIV is treated differently, what U.S. HIV guidelines recommend, and what it means for dating and relationships.

What WHO's vaccine advisers recommended

WHO's Strategic Advisory Group of Experts on Immunization (SAGE) met October 5 to 8, 2026, and reviewed updated evidence on HPV vaccines. According to the SAGE meeting highlights:

• One dose for girls 9 to 14: SAGE recommends a single-dose schedule for girls aged 9 to 14, calling it the most efficient approach to the global goal of eliminating cervical cancer.
• Younger girls, as an option: Countries may consider routine single-dose vaccination of girls aged 4 to 8 if it is likely to raise uptake and coverage.
• Wider catch-up, step by step: Single-dose vaccination may be expanded, in order of priority, to women up to age 25, then women up to age 30, then boys aged 9 to 14, then males up to age 20, with cost-effectiveness and local needs in mind.
• The exception: Immunocompromised people should continue to receive at least two doses. That means two doses for people living with HIV when HIV is well controlled (a CD4 count above 350 cells/mm3), and three doses for people who are severely immunocompromised.

SAGE notes that its full report will be published in WHO's Weekly Epidemiological Record on December 18, 2026, and that only that wording should be considered final. WHO's earlier guidance already allowed one or two doses for girls 9 to 14 and two or three doses for people with weakened immune systems, according to WHO's HPV fact sheet.

Why WHO is pushing one dose

In her October 29 message, Kate O'Brien, director of WHO's Department of Immunization, Vaccines and Biologicals, said 165 countries (85%) have introduced HPV vaccine and more than 95 million girls had received it by the end of 2025. Yet global HPV vaccine coverage was 33% in 2025, far below the 90% target. A single-dose schedule, she wrote, lets countries "extend protection to more girls and young women while making the best possible use of vaccine supplies and programme resources."

Why people living with HIV are treated differently

HPV is more common in some groups. WHO's HPV fact sheet says prevalence is higher among women living with HIV, men who have sex with men and people who are immunocompromised. WHO also advises that women living with HIV be screened for cervical cancer every 3 years starting at age 25, compared with every 5 to 10 years starting at age 30 for other women. Our earlier coverage of HPV cancer risk in people who are immunocompromised looks at why this matters.

New research shows that a full vaccine series can protect women with HIV for years. A Canadian study published October 5, 2026, in The Lancet HIV followed women and girls with HIV who received three doses of the quadrivalent HPV vaccine, for up to 9 years (median 5.9 years).

• Who was studied: 228 participants from 14 clinics across Canada, with a median age of 38.5 at the start.
• Antibodies held up: Antibody levels were similar to those of women without HIV in an earlier comparison group for up to 9 years.
• Some antibodies faded: Among participants who could be evaluated, antibodies dropped back below the positive threshold in 8.5% for HPV16 and in 36.4% for HPV18.
• Low infection and disease: Persistent infection with the vaccine HPV types occurred at 0.52 per 100 person-years and genital warts at 0.37 per 100 person-years. No cases of high-grade cervical precancer (CIN2+) were found.
• Viral load mattered: HIV viral load over time predicted how fast antibodies faded. The authors concluded that keeping HIV suppressed after vaccination "is important to ensure continued protection."

This was an observational cohort without an unvaccinated control group, and it tested the older quadrivalent vaccine, not the 9-valent vaccine used in the U.S. today. Still, it adds reassuring long-term data for women living with HIV.

What U.S. HIV guidelines say

SAGE advises countries worldwide; it does not by itself change U.S. recommendations. In the United States, the federal guidelines for adults and adolescents with HIV (on ClinicalInfo.HIV.gov) recommend:

• Three doses through age 26: People with HIV aged 9 to 26 who haven't been vaccinated should get three doses of the 9-valent HPV vaccine, at 0, 1 to 2, and 6 months. The guidelines say the two-dose series is not recommended for people with HIV.
• Ages 27 to 45: Vaccination isn't routine, but people with HIV who weren't adequately vaccinated can decide with their clinician (shared clinical decision-making) if they may be at risk for a new HPV infection.
• Already vaccinated with an older vaccine: Some experts would consider additional doses of the 9-valent vaccine, but data are lacking.
• Pregnancy: HPV vaccination is not recommended during pregnancy.

Your HIV care provider can tell you which schedule fits you based on your age, history and health.

What it means for dating and relationships

• HPV is common, and it isn't a verdict on anyone. CDC says most sexually active people get HPV at some point, usually without knowing it, and most infections clear on their own. Partners tend to share HPV, and having it does not mean anyone cheated. Our guide on HPV disclosure covers how to talk about it.
• Vaccination is something partners can ask about too. HPV affects people of every gender. See HPV in men: what you need to know. CDC says HPV vaccine can be given regardless of a history of genital warts or an abnormal Pap or HPV test.
• Condoms help but don't cover everything. CDC says consistent, correct condom use can lower the chances of getting and passing HPV, but HPV can infect skin a condom doesn't cover.
• Staying undetectable pays off twice. CDC says people with HIV who take treatment as prescribed and keep an undetectable viral load will not transmit HIV to sexual partners. The Lancet HIV study suggests viral suppression also helps vaccine protection last. See our U=U explainer.
• Screening still matters after vaccination. CDC says vaccinated women should continue routine cervical cancer screening. Our look at at-home HPV screening explains one newer option.
• Date on your own terms. Share health details when you're ready; disclosure expectations and legal duties differ by state. When meeting someone new, meet in a public place, verify who they are, and make sure every step is consensual.

Quick FAQ

Does WHO's one-dose advice apply to adults living with HIV?
No. SAGE says people living with HIV should continue to receive at least two doses (two when HIV is well controlled, three if severely immunocompromised). U.S. HIV guidelines recommend three doses for people with HIV aged 9 to 26.

I'm living with HIV and older than 26. Can I still get the HPV vaccine?
U.S. guidelines don't recommend routine vaccination after 26, but people with HIV aged 27 to 45 who weren't adequately vaccinated can decide with a clinician whether it makes sense for them.

I was vaccinated years ago. Am I still protected?
In the Lancet HIV study, women with HIV who got three doses had low rates of HPV infection and no high-grade cervical precancer over a median of about 6 years, though some antibodies faded, especially for HPV18. Ask your clinician whether anything else is recommended for you.

Can the HPV vaccine treat an HPV infection I already have?
No. CDC says treatments exist for the conditions HPV can cause, such as warts and precancers, but not for the virus itself. That's why WHO focuses on vaccinating girls before they become sexually active.

The bottom line

WHO's advisers are simplifying HPV vaccination for most young people to a single dose, a change aimed at reaching far more girls worldwide. People living with HIV are the exception: the advice is still at least two doses, and U.S. HIV guidelines call for three through age 26. Long-term data show a full series can protect women with HIV for years, especially when HIV stays suppressed. If you're looking for people who understand life with HIV, HPV or herpes, explore STD dating on MeetPositives.

Sources

• World Health Organization. Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization, 5-8 October 2026.
• World Health Organization. "Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO - October 2026." October 29, 2026.
• McClymont E, Blitz S, Nicolls S, et al.; CTN 236 HPV in HIV Study Team. Long-term immunogenicity and efficacy of the quadrivalent human papillomavirus vaccine in women with HIV: a longitudinal cohort study. Lancet HIV. 2026;13(11):e779-e787. doi:10.1016/S2352-3018(26)00204-3.
• Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. "Human Papillomavirus Disease." ClinicalInfo.HIV.gov (reviewed March 16, 2026).
• World Health Organization. "Human papillomavirus and cancer" fact sheet (March 5, 2024).
• CDC. Sexually Transmitted Infections Treatment Guidelines, 2021: "Human Papillomavirus (HPV) Infection."
• CDC. "HIV Treatment as Prevention" (cdc.gov).

This article is for general information only and is not medical or legal advice. It does not create a doctor-patient relationship. Talk with a licensed health care provider about your own situation. Laws vary by state; for legal questions, talk with a licensed attorney.